Pharma Mar SA stock forecast
Pharma Mar SA (PHMMF) Stock Forecast & Price Target
PHMMF Analyst Ratings
PHMMF Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Keay Nakae | Chardan Capital | $110.97 | buy | 52.97%Upside | Reiterated | 08/09/26 | ||
| Kambiz Yazdi | BTIG | $134.27 | buy | 85.10%Upside | Initiated | 04/23/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Keay NakaeChardan Capital | BuyReiterated$110.97 | 08/09/26 | 52.97%Upside | ||
| Kambiz YazdiBTIG | BuyInitiated$134.27 | 04/23/26 | 85.10%Upside |
Best Analysts Covering Pharma Mar SA
Copying Keay Nakae's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +8.16% per trade.
Copying Keay Nakae's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +10.03% per trade.
Copying Keay Nakae's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of +2.17% per trade.
PHMMF Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 3 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 2 | 3 | 1 | 1 | 0 |
In the current month, PHMMF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PHMMF average Analyst price target in the past 3 months is ―.
PHMMF Financial Forecast
PHMMF Earnings Forecast
Next quarter’s earnings estimate for PHMMF is $0.44 with a range of -$0.56 to $1.67. The previous quarter’s EPS was $0.51. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
PHMMF Sales Forecast
Next quarter’s sales forecast for PHMMF is $63.03M with a range of $37.48M to $93.13M. The previous quarter’s sales results were $59.81M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

